Clinical Trials

30 enrolled

Thyroid Carcinoma, Anaplastic

NCT07419932 2026-02-19

NeoLATC

Recruiting

120 enrolled

Thyroid Neoplasms

NCT02231775 2026-02-13

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

58 enrolled

Melanoma

NCT04903119 2026-02-13

Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma

Phase 1 Recruiting

30 enrolled

Melanoma

NCT02910700 2025-12-17

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

52 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT01972347 2025-12-16

Neo Combi

35 enrolled

Fever, Melanoma

NCT03149029 2025-12-05

Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma

16 enrolled 10 charts

Melanoma

NCT04116541 2025-11-21

MegaMOST

455 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT04544111 2025-10-07

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

19 enrolled

Thyroid cancer, Hurthle cell, Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenoma, Oxyphilic, Adenocarcinoma, Follicular

NCT07092670 2025-09-05

MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse.

Recruiting

270 enrolled

Melanoma, Skin Neoplasms

NCT01723202 2025-08-24

Dabrafenib With or Without Trametinib in Treating Patients With Advanced Differentiated Thyroid Cancer

Phase 2 Completed

53 enrolled 11 charts

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT05388877 2025-08-19

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Phase 1 Terminated

13 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT06195228 2025-08-14

A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer

Phase 4 Recruiting

800 enrolled

Advanced Thyroid Cancer Patients Who Received Target Therapy

NCT04238624 2025-07-02

Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer

16 enrolled

Phase 4 Not yet recruiting

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT07010393 2025-06-08

Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

335 enrolled

Thyroid Neoplasms

NCT06712875 2025-05-29

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Phase 1/2 Recruiting

27 enrolled

CNS

Glioma

NCT06978400 2025-05-18

A Study of Dabrafenib Plus Cetuximab/Panitumumab With FOLFOX in the First Line of Therapy in People With Metastatic Colorectal Cancer

64 enrolled

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT06119789 2025-03-26

MATRIX-Rare

Phase 2/3 Not yet recruiting

96 enrolled

Other neoplasm

Rare Malignant Neoplasm

NCT06819605 2025-02-11

NETCAM-RCT

46 enrolled

Ameloblastoma

NCT03026517 2025-01-23

Clinical Trial of Phenformin in Combination With BRAF Inhibitor + MEK Inhibitor for Patients With BRAF-mutated Melanoma

Phase 1 Completed

18 enrolled

Melanoma

NCT02872259 2025-01-14

BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma

Phase 1/2 Completed

74 enrolled

Melanoma

NCT06739395 2024-12-18

Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment Exhaustion

300 enrolled

Other solid neoplasm

Solid Tumor

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

75 enrolled

Locally Advanced Thyroid Gland Carcinoma

NCT02392871 2024-11-27

CombiRT

Phase 1/2 Completed

10 enrolled

Melanoma

NCT04310397 2024-10-30

Dabrafenib, Trametinib, and Spartalizumab for the Treatment of BRAF V600E or V600K Mutation Positive Stage IIIB/C/D Melanoma

Phase 2 Terminated

4 enrolled 8 charts

Melanoma

NCT06653517 2024-10-22

NETCAM

12 enrolled

Ameloblastoma

NCT06532149 2024-08-09

EROS

Recruiting

80 enrolled

OtherThoracic

Carcinoma, Non-Small-Cell Lung, Eunuchism, Erectile Dysfunction, Sexual Dysfunction, Physiological

NCT03455764 2024-07-31

MCS110 With BRAF/MEK Inhibition in Patients With Melanoma

Phase 1/2 Completed

6 enrolled 12 charts

Melanoma

NCT05159245 2024-07-15

FINPROVE

Other hematologic neoplasm

250 enrolled

Hematologic Neoplasms

NCT06362694 2024-04-12

Study of the Rechallenge Concept in Patients With BRAF-positive Anaplastic Thyroid Cancer After Progression on Anti-BRAF Therapy

10 enrolled

Thyroid Carcinoma, Anaplastic

NCT04739566 2024-03-25

ANAPLAST-NEO

Phase 2 Withdrawn

BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Thyroid Carcinoma, Anaplastic

NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1 Terminated

2 enrolled

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT06264778 2024-02-20

Exploration of Fenestration Decompression Combined With Dalafenib in the Treatment of BRAF Mutant Ameloblastoma

Phase 3 Unknown

10 enrolled

Ameloblastoma

NCT05525273 2024-02-14

Swecranio

25 enrolled

CNS

Craniopharyngioma

NCT02367859 2024-01-30

Dabrafenib and Trametinib in Treating Patients With BRAF Mutated Ameloblastoma

Phase 2 Completed

1 enrolled 5 charts

Ameloblastoma, Adamantinoma

NCT02925234 2024-01-24

DRUP

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT05876806 2023-11-30

Dabrafenib Plus Trametinib in Patients With Advanced Solid Tumor Having BRAF V600E Mutation or Clinically Actionable BRAF Gene Alterations

Phase 2 Unknown

30 enrolled

Tumor-Agnostic

Neoplasms

NCT02143050 2023-11-18

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Phase 1/2 Withdrawn

Melanoma

NCT05182931 2023-10-31

I-FIRST

Phase 2 Unknown

80 enrolled

Thyroid Neoplasms

NCT05988697 2023-10-12

Evaluate the Efficacy and Safety of Aspirin in Combination With Trametinib and Dabrafenib

Not yet recruiting

36 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06079333 2023-10-12

NEO-ATACT

20 enrolled

Thyroid Carcinoma, Anaplastic

NCT04059224 2023-09-26

TraMel-WT

Phase 2 Completed

45 enrolled

Melanoma

NCT03272464 2023-09-22

INCB039110 in Combination With Dabrafenib and Trametinib in Patients With BRAF-mutant Melanoma and Other Solid Tumors.

Phase 1 Terminated

1 enrolled 6 charts

Melanoma

NCT05299580 2023-09-14

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Phase 2 Withdrawn